Tag: Pharnext

• Second Phase 3 Clinical Trial for CMT1A “Pleodrug”

  

  After the setback of having to do a second Phase 3 clinical trial, Pharnext’s ongoing drug trials for PXT3003 show positive results in people with CMT1A.

  Dan Knauss

  February 17, 2020

  News, Research

  Acceleron, ACE-083, Baclofen, clinical trials, CMT1A, D-sorbitol, Daniel Cohen, naltrexone hydrochloride, ONLS, Pharnext, pleodrug, pleotherapy, PMP22, PXT3003, Rodolphe Hajj